中华临床免疫和变态反应杂志2017，Vol.11Issue(3)：269-276,8.DOI:10.3969∕j.issn.1673-8705.2017.03.013
艾瑞昔布和塞来昔布治疗中轴型脊柱关节炎的随机平行对照研究
Imrecoxib and Celecoxib for the Treatment of Axial Spondyloarthritis:A Randomized Double-blind Parallel Control Study
摘要
Abstract
Objective To study the effect of selective COX-2 inhibitor on the pain, function and sacroiliac joint magnetic resonance imaging evaluation of axial spondyloarthritis. Methods 120 patients with ax-spondyoarthritis from October 2014 to October 2015 in our hospital were randomly treated with celecoxib or Imrecoxib 0. 2 g, two times daily. The changes of ESR, CRP, BASDAI, BASFI, SPARCC score before and after 12 weeks of treatment were recorded. Results After 12 weeks of treatment, a to-tal of 116 patients completed the follow-up , including 57 cases of Imrecoxib group and 59 cases of the celecoxib group. BASDAI (3. 22±1. 80 vs. 4. 01±1. 77, P=0. 006; 2. 98±1. 49 vs. 4. 19±1. 66, P=0. 000) and ESR [ (14. 85±14. 67) mmol/1 h vs. (20. 58±18. 90) mmol/1 h, P=0. 027;(9. 5±8. 44) mmol/1 h vs. (16. 81±15. 04) mmol/1 h, P=0. 000] and overall evaluation [ (3. 67± 2. 07) vs. (5. 28±2. 30), P=0. 000; (3. 76±2. 08) vs. (5. 55±2. 00), P=0. 000] were statisti-cally significant lower after treatment, Schober test were statistically significantly increased compared to whose after treatment (4. 11±2. 26 vs. 3. 75±2. 05, P=0. 034; 4. 59±2. 78 vs. 3. 90±2. 08, P=0. 016) , BASFI, wall to the ear and lumbar lateral curvature changes were not statistically significant ( P>0. 05 ) . The changes of indicators before and after treatment showed no significant difference be-tween the two groups ( P>0. 05) . Before the treatment the sacroiliac joint SPARCC score was 11. 40 ± 12. 85, SPARCC score was 6. 60 ± 9. 01 after treatment, and the difference was statistically significant ( P<0. 05) . There was no statistically significant differences between the two groups of the changes of SPARCC score ( P>0. 05) . There was statistically significant correlation between the change of ESR, BASFI, lumbar lateral curvature of sacroiliac and joint inflammation ( P<0. 05) . Conclusions Imre-coxib and celecoxib can improve the symptoms and functions of ax-SpA, reduce the sacroiliac joint in-flammation. There are no significant difference between the two drugs. Image changes and the level of ESR are correlated.关键词
脊柱关节炎/选择性COX-2抑制剂/艾瑞昔布/塞来昔布/随机对照Key words
spondyloarthritis/selective COX-2 inhibitors/radiographic progression/imrecoxib/celecoxib分类
医药卫生引用本文复制引用
高冠民,郭艳珂,刘升云,郑朝晖,任翠萍,李贝贝,程敬亮,阚全程,张蕾蕾,郑晓龙,江东彬,李艳敏,徐鹏慧,王国梁,李芝洵,唐俊根..艾瑞昔布和塞来昔布治疗中轴型脊柱关节炎的随机平行对照研究[J].中华临床免疫和变态反应杂志,2017,11(3):269-276,8.基金项目
河南省科技厅基础研究项目, 河南省高等学校重点科研项目计划 (16A320011) （16A320011）
